Skip to main content
NCBI home page
Canadian Family Physician logoLink to Canadian Family Physician
. 1999 Jun;45:1491-1494, 1497-1501.

Zolmitriptan

New product similar to sumatriptan

Zolmitriptan

PMCID: PMC2328451  PMID: 10386213

Abstract

•Zolmitriptan (Zomig) is an antimigraine drug similar to sumatriptan.

•The clinical file mainly comprises placebo-controlled, dose-finding studies recommending an optimal oral dose of 2.5 mg.

•Zolmitriptan has been compared with sumatriptan in a trial that showed no difference in efficacy. In particular, the recurrence rate of headache after initial relief was not lower on zolmitriptan than on sumatriptan.

•The safety profile of zolmitriptan is similar to that of sumatriptan. The contraindications relating to a history of cardiovascular disease must be respected because of the vasoconstrictive effect of the drug.

•Zolmitriptan has the same drug interactions as sumatriptan. Zolmitriptan should not be used during migraine attacks by patients using propranolol.

Full text

PDF
1491

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Edmeads J. G., Millson D. S. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia. 1997 Oct;17 (Suppl 18):41–52. doi: 10.1177/0333102497017S1806. [DOI] [PubMed] [Google Scholar]
  2. Edmeads J. G., Millson D. S. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on > 3000 subjects treated with zolmitriptan. Cephalalgia. 1997 Oct;17 (Suppl 18):41–52. doi: 10.1177/0333102497017S1806. [DOI] [PubMed] [Google Scholar]
  3. Peck R. W., Seaber E. J., Dixon R., Gillotin C. G., Weatherley B. C., Layton G., Posner J. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol. 1997 Dec;44(6):595–599. doi: 10.1046/j.1365-2125.1997.t01-1-00632.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Peck R. W., Seaber E. J., Dixon R., Gillotin C. G., Weatherley B. C., Layton G., Posner J. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br J Clin Pharmacol. 1997 Dec;44(6):595–599. doi: 10.1046/j.1365-2125.1997.t01-1-00632.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1210–1218. doi: 10.1212/wnl.49.5.1210. [DOI] [PubMed] [Google Scholar]
  6. Rapoport A. M., Ramadan N. M., Adelman J. U., Mathew N. T., Elkind A. H., Kudrow D. B., Earl N. L. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1210–1218. doi: 10.1212/wnl.49.5.1210. [DOI] [PubMed] [Google Scholar]
  7. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 (Suppl 18):21–27. doi: 10.1177/0333102497017S1804. [DOI] [PubMed] [Google Scholar]
  8. Rolan P. Potential drug interactions with the novel antimigraine compound zolmitriptan (Zomig, 311C90). Cephalalgia. 1997 Oct;17 (Suppl 18):21–27. doi: 10.1177/0333102497017S1804. [DOI] [PubMed] [Google Scholar]
  9. Schoenen J., Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia. 1997 Oct;17 (Suppl 18):28–40. doi: 10.1177/0333102497017S1805. [DOI] [PubMed] [Google Scholar]
  10. Schoenen J., Sawyer J. Zolmitriptan (Zomig, 311C90), a novel dual central and peripheral 5HT1B/1D agonist: an overview of efficacy. Cephalalgia. 1997 Oct;17 (Suppl 18):28–40. doi: 10.1177/0333102497017S1805. [DOI] [PubMed] [Google Scholar]
  11. Seaber E. J., Ridout G., Layton G., Posner J., Peck R. W. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol. 1997;53(3-4):229–234. doi: 10.1007/s002280050367. [DOI] [PubMed] [Google Scholar]
  12. Seaber E. J., Ridout G., Layton G., Posner J., Peck R. W. The novel anti-migraine compound zolmitriptan (Zomig 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol. 1997;53(3-4):229–234. doi: 10.1007/s002280050367. [DOI] [PubMed] [Google Scholar]
  13. Solomon G. D., Cady R. K., Klapper J. A., Earl N. L., Saper J. R., Ramadan N. M. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1219–1225. doi: 10.1212/wnl.49.5.1219. [DOI] [PubMed] [Google Scholar]
  14. Solomon G. D., Cady R. K., Klapper J. A., Earl N. L., Saper J. R., Ramadan N. M. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. The 042 Clinical Trial Study Group. Neurology. 1997 Nov;49(5):1219–1225. doi: 10.1212/wnl.49.5.1219. [DOI] [PubMed] [Google Scholar]
  15. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group. Headache. 1998 Mar;38(3):173–183. [PubMed] [Google Scholar]
  16. The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. The International 311C90 Long-term Study Group. Headache. 1998 Mar;38(3):173–183. [PubMed] [Google Scholar]
  17. Visser W. H., Klein K. B., Cox R. C., Jones D., Ferrari M. D. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology. 1996 Feb;46(2):522–526. doi: 10.1212/wnl.46.2.522. [DOI] [PubMed] [Google Scholar]
  18. Visser W. H., Klein K. B., Cox R. C., Jones D., Ferrari M. D. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology. 1996 Feb;46(2):522–526. doi: 10.1212/wnl.46.2.522. [DOI] [PubMed] [Google Scholar]

Articles from Canadian Family Physician are provided here courtesy of College of Family Physicians of Canada

RESOURCES